Compare TAC & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TAC | ERAS |
|---|---|---|
| Founded | 1909 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.0B |
| IPO Year | 2001 | 2021 |
| Metric | TAC | ERAS |
|---|---|---|
| Price | $12.48 | $18.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | ★ $23.67 | $14.25 |
| AVG Volume (30 Days) | 1.0M | ★ 4.1M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.57% | N/A |
| EPS Growth | N/A | ★ 36.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.48 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.38 | $1.33 |
| 52 Week High | $17.88 | $24.28 |
| Indicator | TAC | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 40.32 | 53.35 |
| Support Level | $12.16 | $17.36 |
| Resistance Level | $13.06 | $19.96 |
| Average True Range (ATR) | 0.39 | 1.00 |
| MACD | -0.08 | -0.19 |
| Stochastic Oscillator | 16.83 | 50.35 |
TransAlta Corp is an independent power producer based in Alberta, Canada. The company operates a diverse electrical power generation assets in Canada, the United States, and Western Australia. The company has reportable segments namely, Hydro, Wind & Solar, Gas, Energy Transition segment and Corporate Segment. The company generates the majority of its revenue from the gas segment.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.